Streetbeat News

Analyst Ratings

TDOC

Canaccord Genuity analyst Richard Close maintains a Buy rating on Teladoc Health (TDOC) but lowers the price target from $34 to $28.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:19 pm

SPT

Canaccord Genuity analyst David Hynes has reiterated a Buy rating on Sprout Social (NASDAQ:SPT) and maintained a $70 price target.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:18 pm

SEDG

Canaccord Genuity analyst Austin Moeller has reiterated a Hold rating on SolarEdge Technologies (SEDG) and maintained a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:16 pm

RARE

Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $110 to $111.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:14 pm

MIDD

Canaccord Genuity analyst Brian McNamara has maintained a Buy rating on Middleby (NASDAQ:MIDD) and raised the price target from $164 to $166.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:12 pm

MAX

Canaccord Genuity analyst Michael Graham maintains a Buy rating on MediaAlpha (NYSE:MAX) and raises the price target from $18 to $22.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:07 pm

GMED

Canaccord Genuity analyst Caitlin Cronin reiterates a Buy rating on Globus Medical (NYSE:GMED) and maintains a $79 price target.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:05 pm

GMED

Analysts have updated their ratings on Globus Medical (NYSE:GMED), showing a mix of perspectives with an average 12-month price target of $64.75, up from $59.33. The company has shown a revenue growth of 50.95% as of September 30, 2023, but faces challenges in profitability and efficiency, with below-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 2:00 pm

EPD

Enterprise Prods Partners (NYSE:EPD) received diverse analyst ratings over the last three months, with a recent shift towards a more bullish outlook. The average 12-month price target is now $34.0, reflecting a 5.17% increase from the previous target. Despite challenges in revenue growth and profitability, EPD's market capitalization and asset management indicate investor confidence and financial health. Analysts from Truist Securities, RBC Capital, Wells Fargo, and Stifel have updated their ratings and price targets, suggesting a positive short-term outlook for EPD.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 2:00 pm

FUBO

FuboTV (NYSE:FUBO) has been analyzed by 4 analysts, showing a mix of bullish to indifferent ratings. The average 12-month price target is now $4.00, up 23.08% from $3.25. Analysts from Wedbush, Roth MKM, Cantor Fitzgerald, and Needham have provided updates, with price targets ranging from $2.00 to $5.00. FuboTV, a sports-first live TV streaming company, shows a positive revenue trend with a 42.64% growth rate but trails behind industry peers. Its net margin and ROE indicate challenges in financial health and equity utilization.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 2:00 pm